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Abstract Prior activation of mitogen-activated protein kinases
by phorbol 13-myristate 12-acetate (PMA) results in an
inhibition of interleukin (IL)-6-induced activation of the Janus
kinase/signal transducer and activator of transcription (STAT)
signaling pathway which is most likely mediated by the induction
of suppressor of cytokine signaling-3 and requires the specific
SHP2 binding site Y759 of the IL-6 signal transducer gp130. In
this study, we demonstrate that PMA inhibits STAT activation
by IL-6 and the related cytokine leukemia inhibitory factor (LIF)
but not by oncostatin M (OSM). Since the LIF receptor also
contains an SHP2 recruitment site whereas the OSM receptor
lacks such a module, we propose that two SHP2 binding modules
within a homo- or heterodimeric receptor are necessary to
mediate the PMA inhibitory effect. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The Janus kinase (Jak)/signal transducer and activator of
transcription (STAT) pathway transduces the signals of nu-
merous cytokines and growth factors from their respective
surface receptors to target genes in the nucleus. In the case
of the interleukin (IL)-6-type cytokines IL-6, oncostatin M
(OSM), leukemia inhibitory factor (LIF), IL-11, ciliary neuro-
trophic factor (CNTF) and cardiotrophin-1 (CT-1) binding to
their speci¢c receptors induces the homodimerization (IL-6,
IL-11) or heterodimerization (OSM, LIF, CNTF, CT-1) of
the signal transducing receptor chains [1]. Associated Janus
family tyrosine kinases Jak1, Jak2 and Tyk2 become activated
and in turn phosphorylate speci¢c tyrosine residues within the
receptor chains, thereby creating recruitment sites for Src ho-
mology 2 (SH2) domain-containing signaling components
such as STAT1, STAT3 and SHP2 [1^3]. Activated STATs
homo- or heterodimerize, translocate to the nucleus and bind
to regulatory elements of target genes. SHP2 negatively regu-
lates the IL-6-induced gene transcription and links the Jak/
STAT pathway to the mitogen-activated protein (MAP) ki-
nase pathway [4,5].
Phorbol 13-myristate 12-acetate (PMA) is a known activa-
tor of protein kinase C and the Raf-MEK-Erk pathway [6,7].
Recently, it was shown that preincubation of cells with PMA
inhibits the IL-6-induced STAT3 and STAT1 activation [8,9].
This negative e¡ect was found to be dependent on the activa-
tion of MAP kinases and de novo transcription and protein
synthesis. Since PMA leads to a rapid increase of suppressor
of cytokine signaling (SOCS)-3 mRNA, a negative regulator
of the Jak/STAT pathway, we suggested that the inhibitory
e¡ect of PMA on the Jak/STAT pathway is mediated by
SOCS-3. This hypothesis was supported by the ¢nding that
the inhibitory e¡ect of both PMA [9] and over-expressed
SOCS-3 [10] is dependent on tyrosine-759 within the cytoplas-
mic part of gp130. This phosphorylated tyrosine module was
initially found to bind the tyrosine phosphatase SHP2 [11,12].
However, recent ¢ndings suggest that also SOCS-3 can selec-
tively bind to this phosphotyrosine residue thereby exerting its
inhibitory function [10,13].
In this study, we addressed the question whether pre-acti-
vated MAP kinases also inhibit the activation of STAT fac-
tors induced by other IL-6-type cytokines. We ¢nd that PMA
also inhibits the LIF-induced STAT activation but surpris-
ingly not the one by OSM. Using mutant chimeric receptors,
we present evidence that two potential binding sites for SHP2/
SOCS-3 are necessary for the negative e¡ect of PMA.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle’s medium (DMEM) and DMEM/F-12
mix were from Life Technologies, Inc. (Eggstein, Germany), fetal calf
serum from Seromed (Berlin, Germany). PMA was purchased from
Sigma (Deisenhofen, Germany). Recombinant human IL-6 was pre-
pared as described [14,15]. Recombinant human IL-5 was prepared as
described previously [16].
2.2. Cultivation and stimulation of cells
HepG2 cells were grown in DMEM/F-12 mix, and COS-7 cells in
DMEM at 5% CO2 in a water-saturated atmosphere. Culture medium
was supplemented with 10% (v/v) fetal calf serum, streptomycin
(100 mg/l) and penicillin (60 mg/l). Cells grown in a 100 mm dish
to 80% con£uency were preincubated with PMA (1037 M) for
45 min. Cells were then stimulated with IL-6 (10 ng/ml), OSM
(25 ng/ml) or LIF (50 ng/ml) for an additional 15 min.
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2.3. DNA constructs and transfection procedures
Standard cloning procedures were performed. The construction of
pSVL-based expression vectors (Pharmacia) encoding the receptor
chimeras IL-5RK/gp130 and IL-5RL/gp130 has been described in
[17], for the IL-5RL/OSM-R and IL-5RL/LIF-R in [18], for the IL-
5RL/LIF-RY974A in [19]. The integrity of all constructs was veri¢ed
by DNA sequence analyses using an ABI PRISM1 310 Genetic An-
alyzer (Perkin Elmer). COS-7 cells were transfected with 20 Wg total
DNA by using standard calcium phosphate precipitates. Cells were
incubated with the precipitate for 18 h, washed three times with
phosphate-bu¡ered saline (PBS) and cultured in fresh medium for
at least 8 h. Cells were then split and incubated for another 24 h.
2.4. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described in [20]. EMSAs were
performed using a double-stranded 32P-labeled mutated m67SIE oli-
gonucleotide from the c-fos promoter (m67SIE: 5P-GAT CCG GGA
GGG ATT TAC GGG AAA TGC TG-3P) [21,22]. The protein^DNA
complexes were separated on a 4.5% polyacrylamide gel containing
7.5% glycerol in 0.25-fold TBE (20 mM Tris, 20 mM boric acid,
0.5 mM EDTA) at 20 V/cm for 4 h. Gels were ¢xed in 10% methanol,
10% acetic acid and 80% water for 1 h, dried and autoradiographed.
2.5. Immunoprecipitation
Cells were washed twice with PBS and solubilized in 1 ml lysis
bu¡er (0.5% Nonidet P40, 50 mM Tris^HCl, pH 7.4, 150 mM
NaCl, 1 mM NaF, 1 mM EDTA, 1 mM Na3VO4, 0.25 mM PMSF,
5 Wg/ml aprotinin, 1 Wg/ml leupeptin, 1 Wg/ml pepstatin and 15%
glycerol) for 30 min at 4‡C. Insoluble material was removed by cen-
trifugation, and the cell lysate was incubated with speci¢c antibodies
at 4‡C for a minimum of 2 h. The immune complexes were bound to
protein A-Sepharose (5 mg/ml in lysis bu¡er) for 1 h at 4‡C. After
centrifugation, the beads were washed three times with 0.05% Nonidet
P40, 50 mM Tris^HCl, pH 7.4, 100 mM NaCl, 1 mM NaF, 1 mM
EDTA, 1 mM Na3VO4 and 15% glycerol, boiled in gel electrophoresis
sample bu¡er and the eluted proteins were separated on sodium do-
decyl sulfate (SDS)^polyacrylamide (7.5 or 10%) gels. The following
antibody was used: anti-SHP2 rabbit polyclonal antibody (Santa
Cruz, CA, USA).
2.6. Immunoblotting and immunodetection
Electrophoretically separated proteins were transferred onto poly-
vinylidene di£uoride (PVDF) membranes by the semidry Western
blotting method. Non-speci¢c binding was blocked with 10% bovine
serum albumin in TBS-N (20 mM Tris^HCl, pH 7.4, 137 mM NaCl
and 0.1% Nonidet P40) for 15 min. The blots were incubated with
primary antibodies in TBS-N for 1 h. After extensive rinsing with
TBS-N, blots were incubated with secondary antibodies, goat anti-
rabbit IgG or goat anti-mouse IgG conjugated to horseradish peroxi-
dase for 1 h, and developed with the enhanced chemiluminescence
system (ECL, Amersham, Braunschweig, Germany). The following
primary antibodies were used: phosphotyrosine-speci¢c STAT1
(Tyr-701) and STAT3 (Tyr-705) rabbit polyclonal antibodies (New
England Biolabs, MA, USA), anti-phosphotyrosine mouse monoclo-
nal antibody (4G10; Upstate Biotechnology, NY, USA) and anti-
SHP2 rabbit polyclonal antibody (Santa Cruz, CA, USA).
3. Results
Recent ¢ndings of several groups indicate that the IL-6-
induced STAT activation is negatively modulated by pre-acti-
vation of the MAP kinase pathway [8,9,23]. Therefore, we
investigated whether STAT activation induced by other
IL-6-type cytokines (OSM, LIF) is also inhibited by pre-acti-
vated MAP kinases. Human hepatoma HepG2 cells were used
because they are equipped with the speci¢c receptor molecules
for IL-6, OSM and LIF binding.
HepG2 cells were pretreated with 0.1 WM PMA or vehicle
for 45 min before IL-6 (10 ng/ml), OSM (25 ng/ml) or LIF
(50 ng/ml) were added for 15 min. At these concentrations,
maximal STAT activation was achieved (data not shown). In
EMSA, we observed a strong binding of STAT3 to the spe-
ci¢c SIE probe after stimulation of cells with IL-6, OSM or
LIF (Fig. 1A). Upon OSM treatment also STAT1 was acti-
vated. In case of IL-6 and LIF, preincubation of HepG2 cells
with PMA for 45 min resulted in a strongly diminished DNA
binding of STAT3 which in the case of IL-6 is in agreement
with previous observations [8]. In contrast, PMA had no e¡ect
on the OSM-induced STAT activation in HepG2 cells (Fig.
1A).
Since activation of STAT1 and STAT3 requires phosphor-
ylation of speci¢c tyrosine residues, i.e. Tyr-701 in STAT1 and
Tyr-705 in STAT3, we performed Western blot analyses of
nuclear extracts using speci¢c antibodies against the tyro-
sine-phosphorylated forms of these two transcription factors.
Tyrosine phosphorylation of STAT3 was induced by IL-6,
OSM and LIF (Fig. 1B). Incubation with PMA prior to a
stimulation with IL-6 or LIF leads to a diminished tyrosine
phosphorylation, whereas the OSM-induced tyrosine phos-
Fig. 1. Inhibition of IL-6-type cytokine-induced STAT1 and STAT3
activation by PMA. HepG2 cells were pretreated with PMA (1037
M) for 45 min before stimulation with IL-6 (10 ng/ml), OSM (25 ng/
ml) or LIF (50 ng/ml) for 15 min. (A) Cells were harvested, nuclear
extracts were prepared and EMSAs performed as described under
Section 2. (B) 50 Wg of nuclear proteins were separated by 10%
SDS^PAGE and blotted onto PVDF membrane. Membranes were
incubated with (upper panel) phosphospeci¢c STAT1 (Tyr-701) or
(lower panel) phosphospeci¢c STAT3 (Tyr-705) antibodies. Immu-
nogenic proteins were visualized with the ECL system. (C) Cell ly-
sates were prepared and immunoprecipitation with anti-SHP2 anti-
bodies was performed as described under Section 2. Precipitated
proteins were separated by 10% SDS^PAGE, blotted onto PVDF
membrane and analyzed by immunodetection with a speci¢c anti-
phosphotyrosine antibody (4G10) (upper panel). Blots were stripped
and reprobed with anti-SHP2 antibodies (lower panel) for veri¢ca-
tion of equal loading.
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phorylation of STAT3 is not a¡ected. Tyrosine phosphoryla-
tion of STAT1 was only observed after OSM treatment and
was resistant to the inhibitory e¡ect of PMA. These results are
consistent with the data of the EMSA (Fig. 1A). Blots were
stripped and reprobed with antibodies against STAT1 and
STAT3 for veri¢cation of equal loading (data not shown).
Very similar ¢ndings were obtained when the tyrosine phos-
phorylation of the phosphatase SHP2, another down-stream
component of the IL-6-induced JAK/STAT pathway [11,24],
was analyzed. After stimulation of cells with IL-6, LIF or
OSM, a prominent tyrosine phosphorylation of SHP2 was
observed (Fig. 1C). Interestingly, OSM and LIF turned out
to be stronger inducers of SHP2 phosphorylation than IL-6.
PMA inhibited the tyrosine phosphorylation in the cases of
IL-6 and LIF but not after OSM (Fig. 1C). Binding of IL-6 to
its speci¢c K-receptor chain (gp80) leads to a subsequent ho-
modimerization of gp130 receptor subunits, whereas OSM
and LIF trigger the formation of heterodimers. The LIF-R
complex is composed of one gp130 molecule and the speci¢c
LIF-R, whereas OSM can transduce its signal either via a
gp130/LIF-R heterodimer or a gp130/OSM-R dimer. Our
data indicate that PMA negatively modulates signaling via a
gp130 homodimer or a gp130/LIF-R heterodimer but not via
a gp130/OSM-R heterodimer.
To investigate this di¡erential e¡ect of PMA on IL-6-type
cytokine signaling in more detail, we made use of a chimeric
receptor system based on the extracellular parts of the IL-5
receptor K- and L-chains and the transmembrane and intra-
cellular parts of gp130, OSM-R or LIF-R, respectively [17,18].
This system allows the directed formation of homo- and het-
erodimers thereby mimicking the proposed natural receptor
complexes (gp130/gp130, gp130/OSM-R or gp130/LIF-R)
(Fig. 2A). Transient expression of the respective receptor chi-
mera in COS-7 cells and stimulation with IL-5 resulted in a
prominent activation of STAT1 in all three cases (Fig. 2B).
STAT3 is not activated e⁄ciently in these cells unless over-
expressed [12]. Preincubation with PMA led to similar results
as obtained with HepG2 cells : PMA reduced the STAT signal
triggered by the formation of the gp130/gp130 homodimer
and the gp130/LIF-R heterodimer but not signaling via the
gp130/OSM-R heterodimer (Fig. 2B). These data suggest that
the down-regulation of the Jak/STAT pathway by PMA is
dependent on the intracellular part of the participating recep-
tor subunits.
We have recently shown that the inhibitory e¡ect of PMA
on IL-6-induced STAT activation is dependent on tyrosine-
759 of gp130 [9]. The tyrosine phosphatase SHP2 is recruited
to gp130 via its SH2 domains that interact with phosphotyr-
osine-759 of gp130. Furthermore, the negative regulator of the
Jak/STAT pathway SOCS-3 was recently found to mediate its
Fig. 2. (A) Schematic representation of IL-5 chimeric receptors used in this study. Tyrosine residues in the intracellular regions are indicated as
black lines. Mutated tyrosine residues are indicated by asterisks. (B) COS-7 cells were transiently transfected as described under Section 2 with
expression vectors for the chimeric receptors depicted. Cells were preincubated with PMA (1037 M) for 45 min followed by stimulation with
IL-5 (80 ng/ml) for 15 min. Nuclear extracts were prepared and EMSAs performed as described in the legend to Fig. 1.
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inhibitory e¡ect via Y759 [10,13]. The motif Y759STV agrees
well with the consensus sequence YXXL/V/I deduced from
SHP2 binding to other receptors [11,12]. Inspection of the
amino acid sequence of the LIF-R cytoplasmic domain re-
vealed a potential recruitment site, Y974IDV (Fig. 2A, aster-
isks), for SHP2, whereas none could be found in the OSM-R.
In order to examine the role of the YXXL/V/I motifs in the
cytoplasmic tails of gp130 and LIF-R in the PMA-dependent
inhibition of STAT activation, we made use of chimeric IL-5-
RL mutants in which the respective tyrosine residues (Tyr-759
in gp130 and Tyr-974 in LIF-R) were replaced by phenylala-
nine or alanine. We transiently transfected COS-7 cells with
IL-5-RK/gp130 and IL-5-RL/gp130Y759F or IL-5-RK/gp130
and IL-5-RL/LIF-RY974A, respectively, thereby creating re-
ceptor dimers with only one YXXL/V/I motif available in the
homo- or heterodimer after IL-5 stimulation. In both cases,
prestimulation with PMA did not inhibit the IL-5-induced
STAT activation (Fig. 3). These ¢ndings led us to the sugges-
tion that two YXXL/V/I motifs within a receptor dimer are
necessary for the inhibitory e¡ect of PMA.
4. Discussion
Two new ¢ndings are presented in this study. First, in con-
trast to IL-6 and LIF, the OSM-induced STAT activation is
not inhibited by preincubation of cells with PMA. Second,
within the gp130/gp130 homodimer and the LIF-R/gp130 het-
erodimer, respectively, a YXXL/V/I motif in each receptor
subunit is necessary for the inhibitory e¡ect of PMA on the
STAT activation by IL-6-type cytokines.
There is now clear evidence that in respect to the IL-6
receptor complex, both negative regulators of the Jak/STAT
pathway, SHP2 and SOCS-3, elicit their function via the
phosphorylated Y759STV module within the cytoplasmic
tail of gp130 [4,5,10,13,25]. In both cases, an SH2 domain
of the respective protein directly binds to the phosphorylated
module. We have recently found that the inhibition of the IL-
6-induced STAT activation by PMA is most likely mediated
by induction of SOCS-3 and requires interaction of SOCS-3
to phosphorylated Tyr-759 of gp130 [9]. Our ¢nding that sig-
naling via a gp130/gp130 homodimer with only one intact
SHP2/SOCS-3 binding site is not inhibited by PMA (Fig. 3)
suggests that two SOCS-3 molecules have to bind to a gp130/
gp130 homodimer in order to inhibit Jak/STAT signaling.
For the crucial LIF-R module Y974IDV, it has very re-
cently been demonstrated that it interacts with SHP2 [26].
Whether also SOCS-3 binds to the LIF-R SHP2 recruitment
site still has to be established. However, obviously the
Y974IDV module of the LIF-R is analogous to the gp130
Y759STV module in mediating the inhibitory e¡ect of
PMA. In contrast, the OSM-R does not contain an obvious
SHP2/SOCS-3 binding site. Thus, the failure of PMA to in-
hibit OSM signaling could be explained by the fact that within
the gp130/OSM-R heterodimer only one negative regulatory
site is available.
It is currently di⁄cult to discriminate which negative mod-
ulatory e¡ects on Jak/STAT signaling are mediated by SHP2
and which by SOCS-3 since knock-out mice for both are
embryonically lethal [27,28]. However, the fact that in our
scenario the IL-6-type cytokine-induced SHP2 tyrosine phos-
phorylation is impaired by PMA in exactly the same way as
the STAT tyrosine phosphorylation (Fig. 1C) makes a direct
inhibitory role of SHP2 rather unlikely. Also the fact that the
PMA e¡ect is dependent on de novo protein synthesis [9]
excludes a signi¢cant role of SHP2 since this enzyme is ex-
tremely long-lived [29]. Of course, we currently cannot exclude
that additional proteins are involved in the negative regulation
of Jak/STAT signaling by PMA.
It is now well established that the Jak/STAT and the MAP
kinase pathways are interdependent signaling cascades. Both
positive and negative e¡ects of MAP kinases on the activity of
STAT factors have been described. Ser-727 which has been
reported to be the MAP kinase phosphorylation site of
STAT1 as well as STAT3 is required for transcriptional ac-
tivity [30]. Recently, we could show that the hyperosmolarity-
induced STAT1 activation [31] is dependent on the activation
of the p38 MAP kinase [32]. On the other hand, pre-activation
of MAP kinases by di¡erent stimuli was found to inhibit the
subsequent IL-6-induced activation of STAT3 [8,9,33,34]. The
data of this study demonstrate the complexity of these cross-
talk mechanisms in which the inhibitory action of certain
MAP kinases on Jak/STAT signaling does crucially depend
on the stimulus and the involved receptor system.
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